Adaptive Biotechnologies COO Executes Routine 10b5‑1 Sale, Holding 0.48% of Shares Amid Strong Q1 Gains
Insightful look at Adaptive Biotechnologies’ insider sale: rule‑based 10k shares at $16.44, showing disciplined divestment yet strong long‑term stake.
- Adaptive Biotechnologies Corp
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read


